RadNet (RDNT) stock price is $69.27, up 0.68% on the day, as of Oct 19, 2026. It has a market cap of $5.39Bn, and is classified in the Healthcare Services industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap5.39 Bn
P/E-255.33
P/S2.38
Div. Yield0.00
Total Debt (Qtr)1.33 Bn
Revenue Growth (1y) (Qtr)24.99
Add ratio to table…
About
RadNet Inc is a leading national provider of diagnostic imaging services in the United States operating 418 imaging centers across nine states as of December 31 2025. The company was founded in 1985 and has grown through a combination of internal development and strategic acquisitions. Its core business consists of delivering outpatient imaging exams that help physicians detect diagnose and monitor a wide range of medical conditions. The centers offer a full suite of…
RadNet Inc is a leading national provider of diagnostic imaging services in the United States operating 418 imaging centers across nine states as of December 31 2025. The company was founded in 1985 and has grown through a combination of internal development and strategic acquisitions. Its core business consists of delivering outpatient imaging exams that help physicians detect diagnose and monitor a wide range of medical conditions. The centers offer a full suite of modalities including MRI CT PET nuclear medicine mammography ultrasound Xray and fluoroscopy. By locating many centers in dense metropolitan areas RadNet aims to provide convenient access to high quality imaging for patients and referring physicians.
Revenue is derived mainly from two sources: fees for imaging procedures performed at company owned or jointly managed centers and sales of digital health software and services. Imaging fees are collected from third party payors such as commercial insurers managed care organizations Medicare and Medicaid as well as from patients through co pays and deductibles. The company negotiates reimbursement rates with payors and also receives direct payments for services rendered under contract with physician groups. Digital health revenue comes from the sale of RIS PACS workflow platforms AI based image analysis tools and related support and maintenance contracts. These software products are sold to hospitals health systems imaging centers and other healthcare providers in the United States and abroad. The mix of service and technology revenue helps reduce reliance on any single reimbursement stream.
The company reports its operations in two distinct business segments: Imaging Centers and Digital Health. The Imaging Centers segment encompasses all activities related to the operation of outpatient diagnostic imaging facilities. The Digital Health segment includes the development sale and support of software solutions that manage store and interpret medical images.
The Imaging Centers segment operates 418 freestanding outpatient facilities spread across Arizona California Delaware Florida Maryland Virginia New Jersey New York and Texas. These centers provide a broad range of imaging procedures including MRI CT PET nuclear medicine mammography ultrasound Xray and fluoroscopy. Most locations offer multiple modalities allowing patients to receive several types of exams at one site. The segment generates revenue through fees billed to insurance companies government programs and individual patients for each performed study.
The Digital Health segment creates and markets computerized systems for image storage retrieval distribution and reporting. It offers AI powered applications that assist radiologists in detecting abnormalities in mammography lung ultrasound and prostate imaging. Key products include eRad RIS PACS DeepHealth OS and tools acquired from Aidence Quantib ICAD and CIMAR. The segment serves over two thousand customers worldwide ranging from large hospital networks to small private clinics. Revenue is recognized from software licenses maintenance fees and professional services related to implementation and training.
RadNet Inc holds a leading position in the outpatient diagnostic imaging market measured by number of centers and total imaging revenue. The company is frequently cited as the largest freestanding provider of imaging services in the United States. Its scale enables it to secure favorable contracts with national and regional health plans. Competitive advantages include a diversified modality mix strong relationships with referring physician groups and a growing portfolio of digital health technologies. The firm also benefits from a disciplined acquisition strategy that adds volume and geographic depth while integrating operations to achieve cost savings.
The company serves a diverse customer base that includes individual patients seeking diagnostic exams and their referring physicians who order the studies. Hospitals and health systems contract with RadNet both for imaging center joint ventures and for the purchase of digital health software. Insurers such as commercial carriers Medicare and Medicaid pay for services rendered to their members. Additionally the company works with employer groups and occupational health providers that require imaging for workforce health programs. While specific customer names are not disclosed in the filing the breadth of relationships underscores the company’s reach across the healthcare ecosystem.
Sectors:Healthcare·TechnologySector rationaleThe primary business is the operation of 418 outpatient diagnostic imaging centers providing medical exams (MRI, CT, PET, etc.) to patients and physicians, which falls under Healthcare Services. The company also operates a substantial and distinct Digital Health segment that develops and sells RIS/PACS software and AI-based image analysis tools to external healthcare providers, justifying a secondary sector of Technology.Industries:Healthcare ServicesHealthcare ServicesPrimaryRadNet operates 418 freestanding outpatient imaging centers providing MRI, CT, PET, and X-ray exams. Revenue is generated from fees for these procedures paid by commercial insurers, Medicare, Medicaid, and patients.Healthcare ITHealthcare ITSecondaryThe company's Digital Health segment sells RIS, PACS, and AI-based image analysis tools (such as DeepHealth OS) to hospitals and imaging centers. These products are purpose-built for medical image storage, retrieval, and clinical interpretation workflows.Classified using BQ-MICSCIK: 0000790526
Bull & bear
Investment Thesis
▲ Bull case
RadNet's strategic integration of DeepHealth's enterprise AI platform is poised to unlock significant margin expansion and operational leverage beyond current guidance, as evidenced by the company's internal deployments showing tangible efficiency gains like a 33% reduction in ultrasound slot times from 30 to 20 minutes and TechLife reducing exam room closure hours. This productivity enhancement allows RadNet to serve more patients without increasing physical footprint or labor costs, directly improving throughput and revenue per center while mitigating industry-wide technologist shortages. The full rollout of ReportingPro and AI Orchestrator across RadNet's 440-center network will amplify these benefits, converting AI investments into measurable free cash flow growth as deployment capabilities scale, which management acknowledged as a deliberate focus area currently being built to swiftly implement won deals.
The company's aggressive push into health system joint ventures, exemplified by the Trinity Health St. Alphonsus partnership yielding $30 million in annual revenues from just five centers, represents a scalable, high-margin growth avenue that is underappreciated by the market. With 155 of 440 centers already in health system partnerships (35.2%) and a robust pipeline of additional opportunities, RadNet is positioning itself as the preferred operating partner for systems seeking cost-effective outpatient imaging solutions. This model leverages RadNet's AI-powered workflow to deliver seamless inpatient-outpatient integration, a capability health systems cannot optimally achieve internally, creating a structural advantage that drives long-term, sticky revenue streams with lower customer acquisition costs and higher retention versus standalone center growth.
Radian's Digital Health segment is transitioning into a global technology leader with external revenue reaching 64% of total Digital Health revenue in Q1 2026, up from 51% year-over-year, served by an installed base near 3,000 global customers. This shift, combined with a commercial funnel exceeding $150 million in total contract value and $7 million in signed ARR awaiting go-live, indicates that ARR growth is not only on track to exceed the $140 million year-end target but is likely to accelerate into 2027 with momentum building across Diagnostic Suite, Enterprise Operations, and clinical AI. The 95% year-over-year ARR growth to $97 million, coupled with regulatory approval velocity increasing over 70% year-over-year (26 FDA clearances and 22 CE marks currently, with 12 FDA and 15 CE marks expected), signals a self-reinforcing cycle where commercial success fuels further innovation and market expansion, directly supporting the reaffirmed guidance of $135-$145 million in revenue and $10-$12 million in adjusted EBITDA for Digital Health in 2026 with clear upside beyond.
RadNet's strategic integration of DeepHealth's enterprise AI platform is poised to unlock significant margin expansion and operational leverage beyond current guidance, as evidenced by the company's internal deployments showing tangible efficiency gains like a 33% reduction in ultrasound slot times from 30 to 20 minutes and TechLife reducing exam room closure hours. This productivity enhancement allows RadNet to serve more patients without increasing physical footprint or labor costs, directly improving throughput and revenue per center while mitigating industry-wide technologist shortages. The full rollout of ReportingPro and AI Orchestrator across RadNet's 440-center network will amplify these benefits, converting AI investments into measurable free cash flow growth as deployment capabilities scale, which management acknowledged as a deliberate focus area currently being built to swiftly implement won deals.
The company's aggressive push into health system joint ventures, exemplified by the Trinity Health St. Alphonsus partnership yielding $30 million in annual revenues from just five centers, represents a scalable, high-margin growth avenue that is underappreciated by the market. With 155 of 440 centers already in health system partnerships (35.2%) and a robust pipeline of additional opportunities, RadNet is positioning itself as the preferred operating partner for systems seeking cost-effective outpatient imaging solutions. This model leverages RadNet's AI-powered workflow to deliver seamless inpatient-outpatient integration, a capability health systems cannot optimally achieve internally, creating a structural advantage that drives long-term, sticky revenue streams with lower customer acquisition costs and higher retention versus standalone center growth.
Radian's Digital Health segment is transitioning into a global technology leader with external revenue reaching 64% of total Digital Health revenue in Q1 2026, up from 51% year-over-year, served by an installed base near 3,000 global customers. This shift, combined with a commercial funnel exceeding $150 million in total contract value and $7 million in signed ARR awaiting go-live, indicates that ARR growth is not only on track to exceed the $140 million year-end target but is likely to accelerate into 2027 with momentum building across Diagnostic Suite, Enterprise Operations, and clinical AI. The 95% year-over-year ARR growth to $97 million, coupled with regulatory approval velocity increasing over 70% year-over-year (26 FDA clearances and 22 CE marks currently, with 12 FDA and 15 CE marks expected), signals a self-reinforcing cycle where commercial success fuels further innovation and market expansion, directly supporting the reaffirmed guidance of $135-$145 million in revenue and $10-$12 million in adjusted EBITDA for Digital Health in 2026 with clear upside beyond.
RadNet's reliance on advanced imaging growth to drive profitability masks a concerning trend where routine imaging volumes, representing 71% of procedure volume, are nearing stagnation, with management acknowledging they will likely grow only in line with population (low single digits). This shift risks creating a revenue concentration vulnerability, as advanced imaging, while driving over 60% of revenue from just 29.3% of procedures, remains highly sensitive to reimbursement policy changes and utilization fluctuations tied to specific clinical indications like prostate cancer PSMA and brain amyloid PET/CT scans. The company's aggressive focus on upgrading equipment for advanced imaging may inadvertently crowd out routine volume growth opportunities, leaving RadNet exposed if payer policies shift to favor preventive or lower-cost imaging modalities, or if reimbursement for high-margin advanced procedures faces downward pressure amid broader healthcare cost containment efforts.
Despite strong ARR growth in Digital Health, the segment's current adjusted EBITDA margin is intentionally diluted due to strategic investments in deployment capabilities, commercial teams, and infrastructure, with management confirming Q1 2026 is a trough year for margins as per Investor Day plans. This margin pressure is exacerbated by the dilutive impact of recent acquisitions like Gleamer, iCAD, and C-MODE, which are not yet profitable and require significant integration effort, while the path to the long-term 20%-40% EBITDA margin target depends on uncertain factors such as achieving widespread T-code reimbursement for AI solutions (currently limited to thyroid ultrasound with only 60%-70% payer coverage) and successfully monetizing emerging capabilities like breast ultrasound and neuro MR AI. The market may be overestimating the speed at which these AI tools transition from productivity gains to billable revenue, creating a risk that Digital Health remains a drag on consolidated profitability longer than anticipated if deployment lags or reimbursement adoption slows.
RadNet's acquisition-driven growth strategy, while boosting top-line revenue, introduces integration execution risk and financial leverage concerns that are underappreciated given the company's modest but increasing debt profile. The acquisitions of Radiology Regional (13 centers), Northwest Radiology (6 centers), and Gleamer SAS, combined with the Trinity Health joint venture, deployed substantial capital in Q1 2026, increasing net debt to approximately $631 million and maintaining a leverage ratio near 2.0x adjusted EBITDA. Although management emphasizes prudent cash management and expects deleveraging, the success of this strategy hinges on seamless integration of diverse operating systems, cultures, and technologies across geographically dispersed assets—particularly challenging for the international Gleamer integration—and any delays in realizing synergies or achieving projected run rates could pressure free cash flow generation and constrain future M&A capacity, especially if same-center performance fails to consistently offset integration costs.
RadNet's reliance on advanced imaging growth to drive profitability masks a concerning trend where routine imaging volumes, representing 71% of procedure volume, are nearing stagnation, with management acknowledging they will likely grow only in line with population (low single digits). This shift risks creating a revenue concentration vulnerability, as advanced imaging, while driving over 60% of revenue from just 29.3% of procedures, remains highly sensitive to reimbursement policy changes and utilization fluctuations tied to specific clinical indications like prostate cancer PSMA and brain amyloid PET/CT scans. The company's aggressive focus on upgrading equipment for advanced imaging may inadvertently crowd out routine volume growth opportunities, leaving RadNet exposed if payer policies shift to favor preventive or lower-cost imaging modalities, or if reimbursement for high-margin advanced procedures faces downward pressure amid broader healthcare cost containment efforts.
Despite strong ARR growth in Digital Health, the segment's current adjusted EBITDA margin is intentionally diluted due to strategic investments in deployment capabilities, commercial teams, and infrastructure, with management confirming Q1 2026 is a trough year for margins as per Investor Day plans. This margin pressure is exacerbated by the dilutive impact of recent acquisitions like Gleamer, iCAD, and C-MODE, which are not yet profitable and require significant integration effort, while the path to the long-term 20%-40% EBITDA margin target depends on uncertain factors such as achieving widespread T-code reimbursement for AI solutions (currently limited to thyroid ultrasound with only 60%-70% payer coverage) and successfully monetizing emerging capabilities like breast ultrasound and neuro MR AI. The market may be overestimating the speed at which these AI tools transition from productivity gains to billable revenue, creating a risk that Digital Health remains a drag on consolidated profitability longer than anticipated if deployment lags or reimbursement adoption slows.
RadNet's acquisition-driven growth strategy, while boosting top-line revenue, introduces integration execution risk and financial leverage concerns that are underappreciated given the company's modest but increasing debt profile. The acquisitions of Radiology Regional (13 centers), Northwest Radiology (6 centers), and Gleamer SAS, combined with the Trinity Health joint venture, deployed substantial capital in Q1 2026, increasing net debt to approximately $631 million and maintaining a leverage ratio near 2.0x adjusted EBITDA. Although management emphasizes prudent cash management and expects deleveraging, the success of this strategy hinges on seamless integration of diverse operating systems, cultures, and technologies across geographically dispersed assets—particularly challenging for the international Gleamer integration—and any delays in realizing synergies or achieving projected run rates could pressure free cash flow generation and constrain future M&A capacity, especially if same-center performance fails to consistently offset integration costs.